Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$0.17.

  • China Pharma Holdings' EPS (Basic) rose 7384.62% to -$0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.41, marking a year-over-year increase of 16184.21%. This contributed to the annual value of -$0.27 for FY2024, which is 7019.43% up from last year.
  • As of Q3 2025, China Pharma Holdings' EPS (Basic) stood at -$0.17, which was up 7384.62% from -$0.16 recorded in Q2 2025.
  • China Pharma Holdings' 5-year EPS (Basic) high stood at -$0.02 for Q1 2021, and its period low was -$1.2 during Q4 2022.
  • In the last 5 years, China Pharma Holdings' EPS (Basic) had a median value of -$0.22 in 2022 and averaged -$0.33.
  • In the last 5 years, China Pharma Holdings' EPS (Basic) plummeted by 100000.0% in 2022 and then skyrocketed by 8202.25% in 2025.
  • Quarter analysis of 5 years shows China Pharma Holdings' EPS (Basic) stood at -$0.21 in 2021, then crashed by 465.57% to -$1.2 in 2022, then skyrocketed by 69.71% to -$0.36 in 2023, then skyrocketed by 80.75% to -$0.07 in 2024, then plummeted by 142.47% to -$0.17 in 2025.
  • Its last three reported values are -$0.17 in Q3 2025, -$0.16 for Q2 2025, and -$0.24 during Q1 2025.